Wendy L. Bennett, MD, MPH; Sonal Singh, MD, MPH; Jodi B. Segal, MD, MPH
Potential Conflicts of Interest: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M10-2867.
Bennett W., Singh S., Segal J.; An Update on Comparative Effectiveness and Safety of Medications for Type 2 Diabetes. Ann Intern Med. 2011;155:563. doi: 10.7326/0003-4819-155-8-201110180-00021
Download citation file:
Published: Ann Intern Med. 2011;155(8):563.
We appreciate Drs. Goldstein and Mascitelli's letter. We acknowledge growing concerns about the association of diabetes medications and cancer risk (1), and we therefore evaluated cancer as an outcome in our report (2). As Drs. Goldstein and Mascitelli point out, DPP-4 inhibitors have been linked with reports of pancreatic cancer in the FDA's database of reported adverse events (3). Because Elashoff and colleagues examined spontaneous reports to the FDA, they lacked data on the number of patients exposed to DPP-4 inhibitors and could not report on the rate of this outcome (3).
to gain full access to the content and tools.
Learn more about subscription options.
Register Now for a free account.
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only